[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 155″]
Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprised even him?
Learn more about Pravin Dugel, MD here.